Regeneron Pharmaceuticals (REGN) Total Debt (2014 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Total Debt of $2.0 billion for Q2 2026, little changed year-over-year from $2.0 billion in Q2 2025, and little changed quarter-over-quarter from $2.0 billion in Q1 2026.
Regeneron Pharmaceuticals (REGN) Total Debt (2014 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Total Debt history runs 9 years deep, the most recent figure standing at $2.0 billion for Q2 2026.
- In Q2 2026, Total Debt changed 0.1% year-over-year to $2.0 billion; the TTM figure through Jun 2026 stood at $2.0 billion (changed 0.1% YoY), while the FY2025 annual figure was $2.0 billion, changed 0.08% from the prior year.
- Total Debt for Q2 2026 stood at $2.0 billion, roughly flat from $2.0 billion in the prior quarter.
- The five-year high for Total Debt was $2.0 billion in Q2 2026, with the low at $2.0 billion in Q1 2022.
- The 5-year median for Total Debt is $2.0 billion (2024), against an average of $2.0 billion.
- The sharpest annual moves came in 2025 and 2026: Total Debt advanced 0.1% in 2025, then gained 0.07% in 2026.
- Regeneron Pharmaceuticals' Total Debt stood at $2.0 billion in 2022, then increased by 0.08% to $2.0 billion in 2023, then climbed by 0.08% to $2.0 billion in 2024, then advanced by 0.08% to $2.0 billion in 2025, then increased by 0.05% to $2.0 billion in 2026.
- Business Quant data shows REGN's Total Debt at $2.0 billion in Q2 2026, $2.0 billion in Q1 2026, and $2.0 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.07 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.34 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.99 Bn |
| Mar 31, 2026 | 1.99 Bn |
| Dec 31, 2025 | 1.99 Bn |
| Sep 30, 2025 | 1.99 Bn |
| Jun 30, 2025 | 1.99 Bn |
| Mar 31, 2025 | 1.98 Bn |
| Dec 31, 2024 | 1.98 Bn |
| Sep 30, 2024 | 1.98 Bn |
| Jun 30, 2024 | 1.98 Bn |
| Mar 31, 2024 | 1.98 Bn |
| Dec 31, 2023 | 1.98 Bn |
| Sep 30, 2023 | 1.98 Bn |
| Jun 30, 2023 | 1.98 Bn |
| Mar 31, 2023 | 1.98 Bn |
| Dec 31, 2022 | 1.98 Bn |
| Sep 30, 2022 | 1.98 Bn |
| Jun 30, 2022 | 1.98 Bn |
| Mar 31, 2022 | 1.98 Bn |
| Dec 31, 2021 | 1.98 Bn |
| Sep 30, 2021 | 1.98 Bn |